Target intelligence / Profile preview

T cell receptor beta chain Vβ10 region (TCR Vβ10)

Target
TCR Vβ10
Molecular classification
Receptor, Immunoglobulin superfamily (IgSF) domain protein, Adaptive immune receptor
01

Overview

The **T cell receptor beta chain Vβ10 region** represents a specific variable domain (TRBV10) of the β chain of the T cell receptor (TCR), which is a heterodimeric membrane receptor complex critical for antigen recognition by T lymphocytes[3][6][7][1]. The Vβ10 region is one variant among many in the TCR beta chain locus, generated through V(D)J recombination, that provides diversity required for broad antigen detection[6][7]. The TCR, including the Vβ10 region, recognizes peptide fragments presented by major histocompatibility complex (MHC) molecules and thereby triggers T cell activation and subsequent immune responses[3][6]. The structural properties of the Vβ domain, including its unique allosteric and signaling features, enable it to influence receptor specificity and sensitivity[1][2]. Therapies targeting the Vβ10 region (e.g., antibody-fusion molecules like STAR0602) can specifically activate or expand T cell subsets expressing this domain, suggesting a role as a therapeutic target in oncology and immunotherapy[5]. Monitoring the frequency or expansion of Vβ10+ T cells is used as a biomarker of immune activation. Therapeutic agents targeting TCR Vβ10 must be designed to limit risks of nonspecific T cell activation, which can result in adverse immunological effects.

Other names
TCR beta chain Vβ10 regionTRBV10TCR V-beta 10TCRBV10
02

Mechanism of action

Antibody-mediated clustering/cross-linking, resulting in T cell activation and expansion[5]; Modulation of TCR signaling; Enhancement or blockade of antigen-induced T cell responses

03

Biological functions

Antigen recognitionImmune responseT cell activationSignal transduction
04

Disease associations

CancerInfectionAutoimmune diseaseInflammation
05

Safety considerations

Off-target T cell activation and potential cytokine release syndrome when targeted by strong agonists or cross-linking antibodies[5]Risk of general immune activation or immune depletion if over-targetedPotential autoimmunity if Vβ10-targeted therapies break tolerance
06

Interacting drugs

STAR0602 (antibody-fusion molecule targeting Vβ6/Vβ10)[5]

2 more in the full profile.

07

Biomarkers

TCR Vβ10+ T cell frequency as an immune profiling markerExpansion of Vβ10+ T cells in response to antigen or drugSurface expression of Vβ10 (detected by flow cytometry with anti-Vβ10 antibodies)

Beyond the preview

Go deeper on T cell receptor beta chain Vβ10 region (TCR Vβ10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta chain Vβ10 region (TCR Vβ10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call